Proteinuria in sarcoidosis: Prevalence and risk factors in a consecutive outpatient cohort

Amit Chopra¹, Paul Brasher², Haroon Chaudhry³, Robert Zheng³, Arif Asif³, Marc A. Judson³

¹Department of Medicine, Pulmonary and Critical Care Medicine, Albany Medical Center, NY; ²Department of Medicine, Albany Medical College, Albany, NY; ³Department of Medicine, Nephrology, Albany Medical Center, NY

Abstract.

Introduction: While sarcoidosis has been recognized as a potential cause of proteinuria, no study has systematically evaluated the prevalence and risk factors for proteinuria in sarcoid patients. Methods: Consecutive sarcoid patients followed in a university clinic were identified prospectively. All patients with spot urine protein-to-creatinine ratio (UPCR) between 11-2012 and 07-2015 were included in the analysis. Proteinuria was defined as a spot UPCR equal to or exceeding 0.3 mg/mg. The primary goal of the study was to determine the prevalence of proteinuria in this sarcoidosis cohort. Results: Our study cohort consisted of 190 sarcoidosis patients (65% female, 82% white, mean age of 53 years (range 24-88)). Proteinuria was present in 14/190 (7%) of this cohort. Only 5/190 patients (2.5%) had proteinuria who did not have a risk factor for proteinuria. Estimating the 24-hour urine protein excretion by extrapolating from the spot UPCR, proteinuria was moderate in amount (mean 1.60, range 0.32-5.06 mg/mg). Proteinuric patients received a lower mean daily dose of corticosteroids compared to those without proteinuria (0 mg vs 4.7 mg of prednisone); however, this difference did not reach statistical significance (p = 0.20). Conclusion: Our study found proteinuria in 7% of the 190 sarcoid patients. More than half of the patients with proteinuria had a known risk factor for proteinuria other than sarcoidosis. Proteinuria is uncommon in sarcoidosis, and, when it occurs, it should not be assumed that sarcoidosis is the cause without investigating alternative causes of proteinuria. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 142-148)

Key words: proteinuria, sarcoidosis, prevalence

Introduction

Sarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology. The reported prevalence of sarcoidosis renal involvement has been estimated between 3-23% (1). This wide range of incidence estimates suggests that the true incidence of renal involvement in sarcoidosis is unknown. The clinical presentation of renal sarcoidosis can range from an asymptomatic state to acute kidney injury requiring renal replacement therapy. Renal sarcoidosis manifestations vary from kidney disease related to calcium metabolism dysregulation such as nephrocalcinosis, and nephrolithiasis, to granulomatous or non-granulomatous tubule-interstitial nephritis (1,2). Renal failure from sarcoidosis is rare, with reported incidence ranges from 0.7% to 4.3% in previous clinical series of sarcoidosis patients (2).

Proteinuria is an important prognostic factor in stratifying the risk of cardiovascular disease and
chronic kidney disease progression (3-8). In addition to its prognostic significance, successful treatment of proteinuria may reduce the burden of end-stage renal disease, cardiovascular disease, and improve survival (9-11). Only a handful of studies have examined prevalence of proteinuria in renal sarcoidosis. Although these studies have suggested that proteinuria might be common in renal sarcoidosis (12-14), they involved highly selected cohorts. To the best of our knowledge, no study has systematically examined the prevalence and risk factors for proteinuria in sarcoidosis using patient data collected consecutively. We conducted a prospective study of consecutive sarcoidosis patients to determine the prevalence and the risk factors for proteinuria.

Methods

Potential study subjects were identified from a prospective sarcoidosis database that we had previously established at our institution. In these patients sarcoidosis was diagnosed by standardized criteria (15,16). Consecutive patients who had a spot urine protein and creatinine data available in our database at their initial clinic visit between January 2012 and July 2015 were included in the analysis. The following data were obtained concerning each subject from review of the medical records: a) Demographics: Age, gender, race, height, weight, body surface area; b) Comorbidities associated with proteinuria: Diabetes, hypertension, lupus nephritis, Human Immunodeficiency Virus (HIV) infection, hepatitis B and C infection, pregnancy, chronic kidney disease, glomerulonephritis and congestive heart failure; c) Use of medication which can interfere with protein excretion; d) the use of anti-sarcoidosis treatment and anti-sarcoidosis medication; e) serum electrolytes, f) spot urine protein and creatinine.

In this study, proteinuria was defined as spot urine protein-to-creatinine ratio (UPCR) equal to or exceeding 0.3 mg/mg. According to the Kidney Disease Outcomes Quality Initiative guidelines of the US National Kidney Foundation, this method of determining proteinuria is preferred, rather than timed urine collections (24 hr urine protein collection) (17). The spot UPCR in mg/mg is roughly equal to the 24 h protein excretion in g/day/1.73 m² body surface area (18).

We used descriptive statistics for continuous and categorical variables (frequency distributions, percentages, means and standard deviations). Logistic regression model was used for risk prediction of proteinuria. The differences between proteinuria and non-proteinuria groups were obtained by using z-test.

The primary goal of the study was to determine the prevalence of proteinuria in our sarcoidosis cohort. The secondary goal was to identify risk factors associated with proteinuria in our sarcoidosis cohort.

Institutional review board approval was obtained for this study. All study procedures were carried out in accordance with the Declaration of Helsinki regarding research involving human subjects.

Results

One hundred and ninety patients were included in this study. The demographic and clinical characteristics are shown in Table 1. There was no difference in age, sex, or race between the proteinuria and non-proteinuria group. Nearly one third (62/190) of the patients had alternative causes of proteinuria. Proteinuria was present in 14/190 (7%) of total cohort (Figure 1). There was no significant difference in the demographic data between sarcoidosis patients with proteinuria and without proteinuria (Table 2). However, patients with proteinuria had a statistically significant lower mean eGFR as compared to those without proteinuria (56.7 vs 78.7 mL/min/1.73 m², P<0.01). The prevalence of hypertension, diabetes and chronic kidney disease was higher in sarcoidosis patients with proteinuria as compared to those without proteinuria. Estimating the 24-hour urine protein excretion by extrapolating from the UPCR, proteinuria was moderate in amount (mean 1.60, range 0.30-5.06 mg/mg). At the time of spot urine collection, only 45/190 (24%) of the cohort were receiving prednisone at a mean dose of 5 mg/day. Compared to those without proteinuria, patients with proteinuria were receiving a lower mean daily dose of corticosteroids (3.9 mg vs 5.1 mg of prednisone); however, this difference did not reach statistical significance (p = 0.70).

Sixty-eight percent (130/190) of our cohort had no alternative risk factors for proteinuria (diabetes, hepatitis B or C infection, HIV, pregnancy, systemic
lupus erythematosus, congestive heart failure, and glomerulonephritis) and 5/190 patients (2.5%) had proteinuria without any obvious risk factor other than sarcoidosis (Table 3). Proteinuria in these 5 patients was mild to moderate in amount (Mean 0.54, range 0.33-0.81 mg/mg). In these 130 patients without a risk factor for proteinuria, patients with proteinuria had a significantly lower mean eGFR than non-proteinuria (52.2 vs 80.9 mL/min/1.73 m², P<0.01). A higher prevalence of hypertension and chronic kidney disease was noted among patients with proteinuria as compared to non-proteinuria. Fifty percent (7/14) patients with proteinuria had CKD, out of which 2 had biopsy proven renal sarcoidosis and other 2 had nephrolithiasis, that was thought to be secondary to vitamin D dysregulation from sarcoidosis. Patients with proteinuria were more commonly on dihydropyridine and less commonly on ACE inhibitors.

We examined the effect of anti-sarcoidosis treatment on proteinuria. Using 2×2 contingency table with Fischer exact test, there was no significant difference in the use of prednisone between sarcoidosis patients with or without proteinuria (P=0.58) (Data not shown here).
Proteinuria in sarcoidosis

Discussion

This study demonstrates that proteinuria is uncommon in sarcoidosis. More than half of sarcoidosis patients in our cohort with proteinuria had potential alternative causes of proteinuria. Only 5/190 (2.5%) demonstrated proteinuria without being at risk for an alternative cause of proteinuria other than sarcoidosis. Importantly, the proteinuria in this subgroup was mild. Therefore, proteinuria in sarcoidosis patients should not be assumed to be the result of sarcoidosis itself and alternative causes of proteinuria must be carefully considered. Identifying the cause of proteinuria is clinically important, as proteinuria is a strong, independent predictor of increased risk all-cause mortality and cardiovascular mortality in patients (3,4,6,7). Even though the degree of proteinuria was mild in our cohort, those with pro-

Table 2. Comparison of cohort with proteinuria (>0.3g/dl) and non-proteinuria

| Risk factors                      | Proteinuria (N=14) | Non-proteinuria (N=176) | P Value |
|-----------------------------------|--------------------|-------------------------|---------|
| Age                               | 56.2 (26-80)       | 51.6 (25-81)            | 0.32    |
| Mean dose of prednisone (mg)      | 3.9                | 5.1                     | 0.70    |
| Sex, N (%)                        |                    |                         | 1.0     |
| Male                              | 2 (33%)            | 62 (35.2%)              |         |
| Female                            | 4 (67%)            | 114 (64.8%)             |         |
| Race, N (%)                       |                    |                         |         |
| White                             | 4 (67%)            | 144 (82.2%)             | 1.0     |
| Black                             | 2 (33%)            | 27 (15.4%)              |         |
| Other                             | 0                  | 4 (2.4%)                |         |
| Chronic kidney disease*           | 8 (57.1%)          | 12 (6.8%)               | <0.01   |
| Hypertension                      | 10 (71.4%)         | 61 (34.6%)              | 0.028   |
| Risk factors                      |                    |                         |         |
| Diabetes                          | 4 (28.5%)          | 26 (14.7%)              |         |
| Hepatitis B                       | 1 (7.1%)           | 1 (0.6%)                |         |
| Hepatitis C                       | 0 (0%)             | 1 (0.6%)                |         |
| Human Immune Virus                | 1 (7.1%)           | 0 (0%)                  |         |
| SLE                               | 1 (7.1%)           | 1 (0.6%)                |         |
| Congestive heart failure          | 1 (7.1%)           | 4 (2.2%)                |         |
| Pregnancy                         | 0 (0%)             | 0 (0%)                  |         |
| Glomerulonephritis                | 0 (0%)             | 0 (0%)                  |         |
| Chronic kidney disease            | 8 (57.1%)          | 52 (29.5%)              | 0.06    |
| Medications affecting proteinuria |                    |                         |         |
| NSAID                             | 3 (21.4%)          | 26 (14.2%)              |         |
| ACE/ARB                           | 4 (28.5%)          | 41 (23.2%)              |         |
| CCB- Dihydropyridine              | 8 (57.1%)          | 14 (8%)                 |         |
| CCB-Non Dihydropyridine           | 1 (7.1%)           | 4 (2.2%)                |         |
| Cohort taking atleast one medication | 9 (64.3%)       | 49 (27.8%)              | 0.01    |
| Anti-sarcoidosis treatment        |                    |                         |         |
| Prednisone                        | 4 (28.5%)          | 41 (23.2%)              |         |
| Methotrexate                      | 0 (0%)             | 8 (4.5%)                |         |
| Leflunomide                       | 1 (7.1%)           | 1 (0.6%)                |         |
| Hydroxychloroquine                | 0 (0%)             | 7 (4%)                  |         |
| Chloroquine                       | 0 (0%)             | 0 (0%)                  |         |
| Infliximab                        | 0 (0%)             | 7 (4%)                  |         |
| Adalimumab                        | 0 (0%)             | 0 (0%)                  |         |
| Azathioprine                      | 1 (7.1%)           | 3 (1.7%)                |         |
| Mycophenolate                     | 0 (0%)             | 0 (0%)                  |         |
| Cohort taking atleast one anti-sarcoidosis medication | 4 (28.4%)        | 63 (35.7)               | 0.78    |

*: Evidence of kidney damage (pathological, urine abnormality, imaging or blood test) or GFR < 60 NSAID: Non-steroidal anti-inflammatory drug; ACE/ARB= Angiotensin-converting enzyme/Angiotensin II receptor blocker; CCB: Calcium channel blocker, SLE: Systemic Lupus Erythematosus
teinuria had a statistically significantly lower eGFR, suggesting that this subgroup is at risk for potential future renal complications.

Previous estimates of proteinuria in sarcoidosis patients have involved case reports, small case series, or highly selected cohorts. The prevalence of proteinuria was found in 66% of French sarcoidosis patients with histologically proven renal sarcoidosis (13). Berliner and colleagues (12) summarized 94 cases of sarcoid granulomatous interstitial nephritis documented in the literature, and found that 19% (18/94) had proteinuria with the vast majority of patients having

**Table 3.** Comparison of cohort with proteinuria (>0.3 g/dl) and non-proteinuria without alternative causes of proteinuria*

| Demographic/Clinical Characteristic | Proteinuria (N=5) | Non-proteinuria (N=125) | P value |
|------------------------------------|-------------------|-------------------------|---------|
| Age                                | 62.8 (49-80)      | 51.6 (25-81)            | 0.20    |
| Mean dose of prednisone (mg)       | 0                 | 4.7                     | 0.30    |
| eGFR (mL/min/1.73 m²)              | 52.2 (45.7-80)    | 80.9 (25.7-151.4)       | <0.01   |
| Sex, N (%)                         |                   |                         |         |
| Male                               | 1 (20%)           | 47 (38%)                | 1.00    |
| Female                             | 4 (80%)           | 77 (62%)                |         |
| Race, N (%)                        |                   |                         |         |
| White                              | 3 (60%)           | 102 (83%)               |         |
| Black                              | 2 (40%)           | 17 (13%)                | 0.99    |
| Other                              | 0 (0%)            | 4 (3%)                  |         |
| Chronic kidney disease†            | 3 (60%)           | 4 (3.2%)                | <0.01   |
| Hypertension                       |                   |                         | 0.30    |
| Medications affecting proteinuria  |                   |                         |         |
| ACE/ARB                            | 0 (0%)            | 24 (19%)                |         |
| Calcium Channel Blocker            | 3 (60%)           | 7 (6%)                  |         |
| Dihydropyridine                    | 0 (0%)            | 3 (2%)                  |         |
| Non dihydropyridine                | 3 (60%)           | 29 (23%)                |         |
| Cohort taking at least one medication |                 |                         | 0.16    |
| Anti-sarcoidosis medications       |                   |                         |         |
| Prednisone                         | 0 (0%)            | 27 (22%)                |         |
| Methotrexate                       | 0 (0%)            | 5 (4%)                  |         |
| Leflunomide                        | 0 (0%)            | 1 (1%)                  |         |
| Hydroxychloroquine                 | 0 (0%)            | 5 (4%)                  |         |
| Chloroquine                        | 0 (0%)            | 0 (0%)                  |         |
| Infliximab                         | 0 (0%)            | 5 (4%)                  |         |
| Adalimumab                         | 0 (0%)            | 0 (0%)                  |         |
| Azathioprine                       | 0 (0%)            | 3 (2%)                  |         |
| Mycophenolate                      | 0 (0%)            | 0 (0%)                  |         |
| Cohort taking at least one anti-sarcoidosis medication | 0 (0%) | 35 (28%) | 0.38 |

* Diabetic, Systemic lupus erythematosus, HIV, Hepatitis B, Hepatitis C, Glomerulonephritis, Congestive heart failure, Pregnancy, non-steroidal anti-inflammatory use.

†: Evidence of kidney damage (pathological, urine abnormality, imaging or blood test) or GFR < 60 mL/min/1.73m² for ≤ 3 months, with or without kidney damage

**Table 4.** Summary of published studies describing proteinuria in sarcoidosis

| Author (Ref) | N   | Population          | Prevalence of proteinuria | Degree of proteinuria |
|--------------|-----|---------------------|---------------------------|-----------------------|
| Mahevas (13) | 47  | renal sarcoidosis   | 31/47 (66%)               | Mild (median, 0.7 g/24 h; range, 0-2.7 g/24 h) |
| Berliner (12) | 94  | renal sarcoidosis   | 18/94(19%)                | Mild, Majority <1g    |
| Pasquet (14) | 11  | GIN in sarcoidosis  | 9/11 (82%)                | Mild, (Mean 0.84g/24 h; range 0-2g/24 h) |
| Chopra       | 190 | Consecutive sarcoid cases | 5/191 (2.6%) | Mild, (Mean 0.54, range 0.33-0.81 mg/mg) |
proteinuria of 1 g/d or less. In these reports, however, the method used to determine proteinuria was not specified or consistent. These reports did not examine consecutive cases; therefore, these results do not reflect the frequency or severity of proteinuria in an unselected cohort of sarcoidosis patients. In addition, these reports did not address the alternative causes of proteinuria. Finally, patients in those reports had an advanced degree of chronic kidney disease. Unlike the above-cited reports (12,13), we examined consecutive sarcoidosis patients, investigated the alternative causes of proteinuria and used a standard test for the evaluation of proteinuria. We similarly found that the degree of proteinuria was mild. Of the patients in our cohort with proteinuria, 4/14 (29%) had either renal sarcoidosis or nephrolithiasis related to vitamin D dysregulation from sarcoidosis. This suggests that the frequency of proteinuria in sarcoidosis may be much higher than that found in our consecutive patient cohort and approach the frequency in the aforementioned reports of renal sarcoidosis cohorts.

The prevalence of chronic kidney disease and hypertension was higher in sarcoidosis patients with proteinuria as compared to the non-proteinuria cohort. It is conceivable that hypertension might have resulted in mild degree of proteinuria in this group of patients. Compared to sarcoidosis patients without proteinuria, proteinuria patients were prescribed dihydropyridine calcium channel blockers (that may increase proteinuria) more frequently and used ACE inhibitors less commonly; the differences in the use of these anti-hypertensives may have accounted for a portion of the proteinuria cases (19,20).

Our study had several limitations. First, our sample size was relatively small, and very few patients had proteinuria after excluding those with alternative causes of proteinuria, that may have limited our ability to identify risk factors and the effect of anti-sarcoidosis treatment on proteinuria. Second, our cohort was heterogeneous in terms of the point in their clinical course when the spot urine was collected. Some patients had a diagnosis of sarcoidosis recently established, whereas others had carried the diagnosis for many years. Many patients in our cohort did not have a spot urine collected while having evidence of active disease while they were not receiving anti-sarcoidosis therapy. Future studies should address these limitations to accurately assess the presence of proteinuria in sarcoidosis.

In summary, our study revealed that proteinuria is uncommon in sarcoid patients. More than half of the sarcoidosis patients with proteinuria had a known risk factor for proteinuria other than sarcoidosis. Therefore, it should not be assumed that sarcoidosis is the cause without further investigations into the source of proteinuria. When proteinuria is present in sarcoidosis, it is usually mild. Despite the fact that proteinuria is not common in sarcoidosis, the consequences of proteinuria suggest that it should be screened for in all sarcoidosis patients.

Conflicts of Interest:
MAJ: consultant for Jansen, Celgene, Questcor, Mitsubishi-Tanabe, Novartis. AA: No conflict of interest relevant to the project.

Contribution of authors individually:
MAJ is the guarantor of the paper, and takes responsibility for the integrity of the work as a whole, from inception to published article. All authors were involved in the study design. PB, HC, RZ performed the data collection and data entry. All authors contributed to the writing of the manuscript.

References

1. Loffler U, Tulewitz A, Waldherr R, Uppenkamp M, Bergner R. Renal Sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients. Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders 2015; 31(4): 306-15.

2. Bergner R, Hoffmann M, Waldherr R, Uppenkamp M. Frequency of kidney disease in chronic sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG/World Association of Sarcoidosis and Other Granulomatous Disorders 2003; 30(2): 126-32.

3. Agrawal R, Bunaye Z, Bekele DM, Light RP. Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. American journal of nephrology 2008; 28(4): 569-75.

4. Agrawal V, Marinescu V, Agrawal M, McCullough PA. Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nature reviews. Cardiology 2009; 6(4): 301-11.

5. Liu JE, Robbins DC, Palmieri V, et al. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. Journal of the American College of Cardiology 2003; 41(11): 2022-8.

6. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke; a journal of cerebral circulation 1996; 27(11): 2033-9.

7. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney international 1993; 44(3): 638-42.

8. Segura J, Campo C, Ruilope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney international. Supplement 2004 (92): S45-49.

9. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. The New England journal of medicine 1996; 334(15): 939-45.
10. So WY, Ozaki R, Chan NN, et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension 2004; 44(3): 294-9.
11. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110(8): 921-7.
12. Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist’s perspective. American journal of kidney diseases : the official journal of the National Kidney Foundation 2006; 48(5): 856-870.
13. Mahevas M, Lescure FX, Boffa JJ, et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine 2009; 88(2): 98-106.
14. Pasquet F, Chauffer M, Karkowski L, et al. Granulomatous interstitial nephritis: A retrospective study of 44 cases. La Revue de medecine interne / fondée ... par la Societe nationale francaise de medecine interne 2010; 31(10): 670-6.
15. Judson MA. The diagnosis of sarcoidosis. Clinics in chest medicine 2008; 29(3): 415-427, viii.
16. Hunningarhe GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG/World Association of Sarcoidosis and Other Granulomatous Disorders 1999; 16(2): 149-73.
17. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American journal of kidney diseases: the official journal of the National Kidney Foundation 2002; 39(2 Suppl 1): S1-266.
18. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. American journal of kidney diseases: the official journal of the National Kidney Foundation 2007; 50(2): 169-80.
19. Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney international 1998; 53(6): 1559-73.
20. Toto RD, Tian M, Fakouhi K, Champion A, Bacher P. Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. Journal of clinical hypertension 2008; 10(10): 761-9.